Clinical Trials Logo

Filter by:
NCT ID: NCT02987400 Completed - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Start date: January 4, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical activity and tolerability of a combination of obinutuzumab plus venetoclax in patients with relapsed or refractory diffuse large B-cell lymphoma.

NCT ID: NCT02986750 Completed - Dry Eye Syndromes Clinical Trials

Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome

Start date: February 13, 2016
Phase: Phase 4
Study type: Interventional

Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease. However, exact information about influence on tear film thickness and corneal residence time of topical lubricants is still sparse, therefore no ideal treatment regimen has been found. Recently a new method for assessment of tear film thickness based on ultra-high resolution optical coherence tomography (OCT) has become available. The aim of the present study is to assess the influence on tear film thickness of three different formulations of topical lubricants, in particular Thealoz Duo® Eye Drops, Optive® Eye Drops and Systane Ultra® Eye Drops in patients with moderate to severe dry eye disease. In addition, standard tests for dry eye syndrome, such as the ocular surface disease index (OSDI©), Schirmer I test, corneal fluorescein staining and determination of tear break up time (BUT) will be performed to compare the product effects.

NCT ID: NCT02986724 Completed - Crohn Disease Clinical Trials

A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)

CHRONOS
Start date: January 4, 2017
Phase:
Study type: Observational

The purpose of this non-interventional study (NIS) study is to assess further knowledge on the routine use of Entyvio in inflammatory bowel disease therapy, particularly the use in participants with CD and UC naive to biologics.

NCT ID: NCT02981472 Completed - Thrombosis Clinical Trials

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Start date: January 19, 2017
Phase: Phase 2
Study type: Interventional

To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.

NCT ID: NCT02980913 Completed - Dry Eye Syndromes Clinical Trials

Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome

Start date: February 11, 2016
Phase: N/A
Study type: Interventional

Dry eye syndrome is a highly prevalent ocular disease with an increasing incidence in the elderly population. Topically administered lubricants are the basis for treatment of this disease. Relief of symptoms in patients with moderate to severe dry eye disease is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels.

NCT ID: NCT02979899 Completed - Clinical trials for Advanced Angiosarcoma

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

TAPPAS
Start date: February 13, 2017
Phase: Phase 3
Study type: Interventional

This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.

NCT ID: NCT02979288 Completed - Clinical trials for Lactobacillus Infection

Treatment of the Intermediate Vaginal Microbiota With Vaginal Lactobacillus Casei Rhamnosus to Improve Pregnancy Outcome

LCR35&PTD
Start date: May 2, 2017
Phase: Phase 3
Study type: Interventional

In the currently presented trial, investigators aim to evaluate the treatment of the intermediate vaginal microbiota during the first trimester of pregnancy with vaginal lactobacilli to restore the normal vaginal microbiota and therewith reduce the rate of PTD. All pregnant women between 10 + 0 (10 weeks plus 0 days) and 16 + 0 (16 weeks plus 0 days) gestational weeks in study group will be treated with vaginal Lactobacilli Capsules containing L. Casei rhamnosus LCR 35

NCT ID: NCT02976753 Completed - Hemophilia A Clinical Trials

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

Start date: December 2016
Phase:
Study type: Observational

The purpose of the study is to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A over a 24-month prospective period. Data will also be collected for a 12 month retrospective period.

NCT ID: NCT02976129 Completed - Crohn's Disease Clinical Trials

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

HarbOR
Start date: December 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease (CD).

NCT ID: NCT02970942 Completed - Clinical trials for Non-alcoholic Steatohepatitis

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Start date: November 30, 2016
Phase: Phase 2
Study type: Interventional

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis